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Summary End-stage chronic obstructive pulmonary disease often leads to hypercap-
nic respiratory failure. Oxygen supplementation therapy may further aggravate
hypercapnia and not all patients are compliant with non-invasive ventilation. This
case documents successful control of chronic respiratory failure with medroxypro-
gesterone in a postmenopausal woman during 1-year follow-up.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
The prevalence of chronic obstructive pulmonary
disease (COPD) is increasing in both men and in
women. Non-invasive ventilation is proposed for
the hypercapnic respiratory failure in end-stage
COPD but not all patients are compliant. In non-
compliant patients, respiratory stimulation with
progestins1,2 could be an option in those whose
progesterone receptors are not down-regulated by
high levels of androgen, i.e. in women.3 We
previously showed that medroxyprogesterone acet-
ate (MPA) markedly improves arterial blood gases in
short term in chronic respiratory insufficiency.4 In
postmenopausal women, the beneficial respiratory
effects were maintained at least for 3 weeks after
cessation of MPA therapy.4,5 Whether these bene-
ficial effects are maintained long term is not
known.
Case report
We followed the effects of a cyclic MPA therapy in a
76-year old woman with severe COPD and chronic
respiratory insufficiency. Despite maximal bronch-
odilator therapy, her forced expiratory volume was
1.49 l (68% of predicted) and forced expiratory
volume in one second 0.87 l (50% of predicted).
Because of her tendency for carbon dioxide reten-
tion, she was not eligible for long-term oxygen
therapy. She was not willing to use non-invasive
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ventilation, and continued to suffer from regular
morning headaches. A cyclic regimen of 2 weeks on
and off MPA 60mg daily was started. MPA was
divided in two doses of 30mg each, which were
administered in the evening 2 h apart to achieve
maximum concentrations during night. There were
no changes in her regular medication except
introducing MPA. No oral steroids, antibiotics,
neurological medicines or analgetics were adminis-
tered. Her blood gases improved and her morning
headaches vanished with treatment.
Due to tenderness of her breasts, MPA dose was
halved during the second cycle, but her blood gases
deteriorated. The gradual increase of MPA back to
the dose of 60mg per day was successful without
side effects. By now, our patient has used MPA on a
cyclic regimen for 12 months, and her blood gases
have continued to improve (Table 1). MPA seems to
maintain its efficacy in long term and is well
tolerated. Despite respiratory stimulation, her
nocturnal and exertional dyspnoea improved rather
than aggravated. The initial tenderness of breasts
was the only adverse effect observed. The patient
attributed her improved quality of life to the
therapy and preferred to continue.
Discussion
MPA stimulates breathing in males1,2 and in
females.4 However, studies investigating the long-
term efficacy and feasibility of progestins to
control respiratory insufficiency are lacking. Our
case study suggests that blood gases, morning
headaches and quality of life may markedly
improve during progestin therapy in patients with
respiratory failure due to end-stage COPD. The
present case report also provides evidence that the
beneficial effects are maintained in long-term
therapy.
Based on our previous observations of prolonged
respiratory effects in postmenopausal women, our
patient used MPA on a cyclical basis.4,5 The
prolonged effect seems to be specific for
women, since in healthy men the ventilatory
effects subside within 14 days after a 2-week
treatment with MPA of 60mg daily.2 Progesterone
concentrations are low in both men and postmeno-
pausal women but down-regulation of progesterone
receptors by androgens,3 may shorten the progestin
effect in men. In premenopausal women, the
secretory pattern of progesterone is strongly
affected by the phase of the menstrual cycle.
Therefore, it may be more physiological to admin-
ister progestins on a cyclical than on a continuous
basis.
Patients with end-stage COPD often need hospi-
talisation due to hypercapnic respiratory failure.
Therefore, any new treatment options to avoid
hypercapnia would be of high interest. Selected
cases of respiratory insufficiency could respond to
progestins with respiratory stimulation. Compre-
hensive studies into the feasibility and the efficacy
of long-term MPA therapies in postmenopausal
women are therefore warranted.
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Table 1 Arterial blood gases at baseline and during medroxyprogesterone acetate therapy while breathing room
air.
Parameter Before MPA During MPA
Preceding
6 months
Baseline 6 months 9 months 12 months
PaCO2 (kPa) 5.7–7.6 6.8 4.9 5.0 4.5
PaO2 (kPa) 5.1–5.9 6.1 6.6 7.3 7.6
pH 7.33–7.44 7.37 7.48 7.46 7.47
HCO3 (mmol/l) 26.7–41.9 26.0 26.8 26.3 25.1
BE (mmol/l) 3.2–8.1 2.2 2.9 2.2 0.9
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